A randomized, double blind, placebo controlled, parallel, multicenter,phase 3 study on genetic and clinical evaluation of probiotic bacillus Coagulans strain in patients with irritable bowel syndrome. - NIL

开始日期2024-03-25

申办/合作机构

Vidya Herbs Pvt Ltd.

RPCEC00000430 / Suspended临床1期IIT

Safety evaluation of Bacillus coagulans AO1167 for its use as a probiotic in humans

开始日期2023-09-05

申办/合作机构-

CTRI/2022/09/045755 / Completed临床4期

A Randomized, Double-Blind, Active-Controlled, 4-week Parallel GroupStudy to Evaluate the Efficacy and Safety of Lactitol and Probiotic Bacillus Coagulans SC208 in patients with Chronic Idiopathic Constipation. - Lactiliq-TM Syrup

开始日期2022-10-31

申办/合作机构

Synergia Life Sciences Pvt Ltd.

[+1]

100 项与凝结芽孢杆菌活菌(青岛东海药业) 相关的临床结果

登录后查看更多信息

100 项与凝结芽孢杆菌活菌(青岛东海药业) 相关的转化医学

登录后查看更多信息

100 项与凝结芽孢杆菌活菌(青岛东海药业) 相关的专利（医药）

登录后查看更多信息

119

项与凝结芽孢杆菌活菌(青岛东海药业) 相关的文献（医药）

2024-08-01·Food Chemistry

Cereal flours with Bacillus coagulans and beta-glucan: Technological properties and sensory acceptability

Article

作者: Cardarelli, Haíssa Roberta ; Grisi, Cristiani Viegas Brandão ; Cardoso, Paula Izabela Felinto da Costa ; Vieira, Érica de Andrade ; de Almeida, Dayanne Kelly Lopes

This study aimed to develop three formulations of cereal flours: control cereal flour (CCF), probiotic cereal flour (PCF), and symbiotic cereal flour (SCF), and porridges from the flours were manufactured as a functional food. No significant differences were observed in the microbiological quality and the color of the flours for 150 days. The technological and functional potential of the flours were variously improved with the addition of Bacillus coagulans as a probiotic and beta-glucan as a prebiotic. The addition of beta-glucan fiber did not change the viability of the probiotic, which was higher than 7.45 log CFU/g for SCF and 7.13 log CFU/g for PCF until the end of the storage period. All porridge samples showed non-Newtonian fluid behavior with pseudoplastic characteristics; and the PCF and SCF porridges differed regarding the parameters of hardness (1.10 to 1.38 N), adhesiveness (5.88 to 8.86 mJ), cohesiveness (0.78 to 0.95) and gumminess (0.93 to 1.52 N) over time. The addition of the beta-glucan prebiotic interfered with these attributes due to its gelling capacity in the presence of water. The PCF obtained the best sensory acceptance scores when compared to the other formulations. The addition of Bacillus coagulans and beta-glucan did not interfere with thermographic behavior. The SCF differed in the observed crystallinity parameters from CCF and PCF, with the presence of larger solids and agglomerates.

2024-06-01·Pharmacological Research

Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance

Article

作者: Wang, Wei ; Xue, Jing ; Wang, Ting ; Xu, Ming ; Zhang, Zhihan ; Wang, Huaizhi ; Zhang, Zhengyan

The existing body of research underscores the critical impact of intratumoral microbiomes on the progression of pancreatic ductal adenocarcinoma (PDAC), particularly in reshaping the tumor microenvironment and influencing gemcitabine resistance. However, peritumoral tissues' microbiome, distinct from PDAC tumors, remain understudied, and Western-centric analyses overlooking potential variations in dietary-influenced microbiomes. Our study addresses this gap by 16 S rRNA sequencing of PDAC tumors and matched peritumoral tissues from Chinese Mainland patients. Our research has uncovered that the microbiome composition within tumors and paired peritumoral tissues exhibits a high degree of similarity, albeit with certain discrepancies. Notably, Exiguobacterium is found to be more abundant within the tumor tissues. Further investigations have revealed that a lower Exiguobacterium/Bacillus ratio in both the tumor and peritumoral tissues of PDAC patients is indicative of a more favorable prognosis. Further exploration utilizing an orthotopic tumor model demonstrates that the probiotic Bacillus Coagulans impedes PDAC progression, accompanied by an increased infiltration of inflammatory neutrophils in tumors. Additionally, in the subgroup with a low Exiguobacterium/Bacillus ratio, whole-exome sequencing reveals elevated missense mutations in ABL2 and MSH2. The elevated expression of ABL2 and MSH2 has been correlated with poorer prognostic outcomes in PDAC patients. Together, these insights shed light on risk factors influencing PDAC progression and unveil potential therapeutic targets, alongside probiotic intervention strategies.

2024-05-01·Veterinary Medicine and Science

Effect of Bacillus subtilis and Bacillus coagulans spores on induced allergic contact dermatitis in dogs

Article

作者: Khosravi, Mohammad ; Zayerzadeh, Akram ; Razijalali, Mohammad ; Avizeh, Reza ; Gharibi, Darioush

AbstractBackgroundProbiotic strains have the potential to modulate immune responses, reduce intestinal inflammation, normalize intestinal mucosal function and decrease allergic reactions.ObjectiveThis study aimed to investigate the effect of oral probiotic supplements containing Bacillus subtilis and Bacillus coagulans spores on clinical symptoms, haematological factors and immune responses to allergic contact dermatitis in dogs induced by dinitrochlorobenzene (DNCB).MethodsDNCB was injected subcutaneously into the scapular region of 20 healthy adult dogs of both sexes, divided into four groups, to induce experimental allergic contact dermatitis. Dogs in Group 1 received food without probiotics or medication. Oral prednisolone was administered to Group 2 for 30 days at a dosage of 0.25 mg/kg every other day. The dogs in Group 3 were treated with a combination of oral prednisolone and probiotics. The dogs in Group 4 were fed daily with a mixture of 109B. subtilis and B. coagulans bacteria for 30 days. The immune system responses and related gene expression were analysed in the treated animals.ResultsThe administration of probiotics for 30 days resulted in a reduction in clinical symptoms and duration of wound repair. The probiotics treatment also significantly increased the serum bactericidal effects against Staphylococcus aureus and Escherichia coli. It enhanced both the classic and alternative activity of the complement, as well as lysozyme activity. Additionally, the probiotics led to higher total immunoglobulin levels and significant reductions in anti‐trypsin and C‐reactive protein levels. Furthermore, the expression of IgE, induction of interferon‐gamma and IL‐4 genes were also reduced.ConclusionsAccording to the results, B. subtilis and B. coagulans can be further investigated as a viable alternative to corticosteroids in treating allergic contact dermatitis in dogs.

项与凝结芽孢杆菌活菌(青岛东海药业) 相关的新闻（医药）

2023-12-31

·蒲公英Ouryao

药典委：20个生物制品标准草案公示

转自：药典委编辑：水晶12月28-29日，药典委公示了20个标准草案。人生长激素注射液；地衣芽孢杆菌活菌颗粒、蜡样芽孢杆菌活菌片、凝结芽孢杆菌活菌片、酪酸梭菌活菌片、酪酸梭菌活菌散、酪酸梭菌活菌胶囊、蜡样芽孢杆菌活菌胶囊、地衣芽孢杆菌活菌胶囊；人用抗体偶联药物制品总论通则3302外源病毒因子检查法、通则3431质粒DNA构象测定法、通则核酸酶残留量测定法（核酸荧光底物法）；生物制品检定用动物细胞基质制备及质量控制、生物制品生产用动物细胞基质制备及质量控制；基于假病毒的中和抗体检测法指导原则；冻干静注乙型肝炎人免疫球蛋白（pH4）、静注乙型肝炎人免疫球蛋白（pH4）、冻干静注人免疫球蛋白（pH4）、静注人免疫球蛋白（pH4）。其中：3302 外源病毒因子检查法公示稿修订说明：按照“生物制品生产检定用动物细胞基质制备及质量控制”修订情况，增加昆虫细胞的内容。冻干静注乙型肝炎人免疫球蛋白（pH4）公示稿修订说明：按《中国生物制品命名原则》以及同类制品“冻干静注人免疫球蛋白”的命名情况，修订名称。静注乙型肝炎人免疫球蛋白（pH4）公示稿修订说明：按《中国生物制品命名原则》以及同类制品“静注人免疫球蛋白”的命名情况，修订名称。静注人免疫球蛋白（pH4）公示稿修订说明：1、按《中国生物制品命名原则》以及目前国内静注人免疫球蛋白的实际批准情况，修订名称。2、根据实际情况修订 pH 值检定项目。更多内容。请“阅读原文”下载附件。

微生物疗法

100 项与凝结芽孢杆菌活菌(青岛东海药业) 相关的药物交易

登录后查看更多信息